- Adaptive Biotechnologies (ADPT, Financial) sees significant revenue growth, fueled by clinical demand and improved pricing.
- Wall Street analysts predict a 33.61% upside potential, with a high estimate target price of $12.00.
- GF Value estimates suggest the stock is trading below its fair value, indicating a promising investment opportunity.
Adaptive Biotechnologies (ADPT) has reported an impressive start for the first quarter of 2025, showcasing a robust 25% year-over-year revenue increase, reaching $52.4 million. The company’s MRD revenue surged by 34%, attributed to strong clinical demand and improved pricing strategies. A milestone achievement includes securing its first Medicare coverage for MCL monitoring, while sequencing gross margins rose to a strong 62%.
Wall Street Analysts Forecast
Analysts are optimistic about Adaptive Biotechnologies Corp (ADPT, Financial), with six analysts providing a one-year average target price of $9.83, reflecting a potential 33.61% upside from its current price of $7.36. Forecasts vary, ranging from a high of $12.00 to a low of $7.00. Investors can explore detailed estimates on the Adaptive Biotechnologies Corp (ADPT) Forecast page.
In terms of brokerage recommendations, Adaptive Biotechnologies Corp scores an average recommendation of 1.9 from eight firms, indicating an "Outperform" status. The rating system, where 1 signifies a "Strong Buy" and 5 indicates "Sell," positions ADPT favorably within the market.
GuruFocus’s analytical estimates position the GF Value for Adaptive Biotechnologies Corp at $8.32 in the upcoming year. This indicates a projected 13.04% upside from its current trading price of $7.36. The GF Value metric provides a calculated fair value, derived from historical stock multiples, past business growth, and future performance estimates. For more in-depth analysis, visit the Adaptive Biotechnologies Corp (ADPT, Financial) Summary page.
